492 related articles for article (PubMed ID: 29127682)
1. Genome Editing for the β-Hemoglobinopathies.
Porteus MH
Adv Exp Med Biol; 2017; 1013():203-217. PubMed ID: 29127682
[TBL] [Abstract][Full Text] [Related]
2. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.
Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L
Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy for β-Hemoglobinopathies.
Cavazzana M; Antoniani C; Miccio A
Mol Ther; 2017 May; 25(5):1142-1154. PubMed ID: 28377044
[TBL] [Abstract][Full Text] [Related]
4. A New Era for Hemoglobinopathies: More Than One Curative Option.
Psatha N; Papayanni PG; Yannaki E
Curr Gene Ther; 2017; 17(5):364-378. PubMed ID: 29357790
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease.
Germino-Watnick P; Hinds M; Le A; Chu R; Liu X; Uchida N
Cells; 2022 Jun; 11(11):. PubMed ID: 35681538
[TBL] [Abstract][Full Text] [Related]
6. Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells.
Cromer MK; Camarena J; Martin RM; Lesch BJ; Vakulskas CA; Bode NM; Kurgan G; Collingwood MA; Rettig GR; Behlke MA; Lemgart VT; Zhang Y; Goyal A; Zhao F; Ponce E; Srifa W; Bak RO; Uchida N; Majeti R; Sheehan VA; Tisdale JF; Dever DP; Porteus MH
Nat Med; 2021 Apr; 27(4):677-687. PubMed ID: 33737751
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells.
Dever DP; Bak RO; Reinisch A; Camarena J; Washington G; Nicolas CE; Pavel-Dinu M; Saxena N; Wilkens AB; Mantri S; Uchida N; Hendel A; Narla A; Majeti R; Weinberg KI; Porteus MH
Nature; 2016 Nov; 539(7629):384-389. PubMed ID: 27820943
[TBL] [Abstract][Full Text] [Related]
8. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.
Traxler EA; Yao Y; Wang YD; Woodard KJ; Kurita R; Nakamura Y; Hughes JR; Hardison RC; Blobel GA; Li C; Weiss MJ
Nat Med; 2016 Sep; 22(9):987-90. PubMed ID: 27525524
[TBL] [Abstract][Full Text] [Related]
9. Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells.
Moiani A; Letort G; Lizot S; Chalumeau A; Foray C; Felix T; Le Clerre D; Temburni-Blake S; Hong P; Leduc S; Pinard N; Marechal A; Seclen E; Boyne A; Mayer L; Hong R; Pulicani S; Galetto R; Gouble A; Cavazzana M; Juillerat A; Miccio A; Duclert A; Duchateau P; Valton J
Nat Commun; 2024 Jun; 15(1):4965. PubMed ID: 38862518
[TBL] [Abstract][Full Text] [Related]
10. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
[TBL] [Abstract][Full Text] [Related]
11. Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy.
Rosanwo TO; Bauer DE
Mol Ther; 2021 Nov; 29(11):3163-3178. PubMed ID: 34628053
[TBL] [Abstract][Full Text] [Related]
12. Base editing of haematopoietic stem cells rescues sickle cell disease in mice.
Newby GA; Yen JS; Woodard KJ; Mayuranathan T; Lazzarotto CR; Li Y; Sheppard-Tillman H; Porter SN; Yao Y; Mayberry K; Everette KA; Jang Y; Podracky CJ; Thaman E; Lechauve C; Sharma A; Henderson JM; Richter MF; Zhao KT; Miller SM; Wang T; Koblan LW; McCaffrey AP; Tisdale JF; Kalfa TA; Pruett-Miller SM; Tsai SQ; Weiss MJ; Liu DR
Nature; 2021 Jul; 595(7866):295-302. PubMed ID: 34079130
[TBL] [Abstract][Full Text] [Related]
13. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
Paschoudi K; Yannaki E; Psatha N
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
[TBL] [Abstract][Full Text] [Related]
14. In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies.
Li C; Georgakopoulou A; Newby GA; Everette KA; Nizamis E; Paschoudi K; Vlachaki E; Gil S; Anderson AK; Koob T; Huang L; Wang H; Kiem HP; Liu DR; Yannaki E; Lieber A
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36006707
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.
Magrin E; Miccio A; Cavazzana M
Blood; 2019 Oct; 134(15):1203-1213. PubMed ID: 31467062
[TBL] [Abstract][Full Text] [Related]
16. Extending Gene Medicines to All in Need.
McCune JM; Kiem HP
N Engl J Med; 2024 May; 390(18):1721-1722. PubMed ID: 38657269
[No Abstract] [Full Text] [Related]
17. Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.
Dong AC; Rivella S
Adv Exp Med Biol; 2017; 1013():155-176. PubMed ID: 29127680
[TBL] [Abstract][Full Text] [Related]
18. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
[TBL] [Abstract][Full Text] [Related]
19. Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.
Negre O; Eggimann AV; Beuzard Y; Ribeil JA; Bourget P; Borwornpinyo S; Hongeng S; Hacein-Bey S; Cavazzana M; Leboulch P; Payen E
Hum Gene Ther; 2016 Feb; 27(2):148-65. PubMed ID: 26886832
[TBL] [Abstract][Full Text] [Related]
20. Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials.
Segura EER; Ayoub PG; Hart KL; Kohn DB
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]